Quick Menu

Upcoming Journals
  • No Upcoming Journals

British Journal of Medicine and Medical Research

British Journal of Medicine and Medical Research, ISSN: 2231-0614,Vol.: 3, Issue.: 4 (October-December)

 

Case Study

 

Severe Symptomatic Hypocalcemia after Denosumab Administration in an End-Stage Renal Disease Patient on Peritoneal Dialysis with Controlled Secondary Hyperparathyroidism

 

 

Mohit Agarwal1*, Éva Csongrádi1,2, Christian A. Koch1, Luis A. Juncos1, Vonda Echols1, Mihály Tapolyai3 and Tibor Fülöp1

1Department of Medicine, University of Mississippi Medical Center, Jackson, MS, USA.
2Department of Medicine, Medical and Health Science Centre University of Debrecen, Hungary.
3Fresenius Medical Care, Semmelweis University, Budapest, Hungary.

 

Abstracts

 

We report the 1st case of severe, symptomatic hypocalcemia after denosumab (RANKL inhibitor) treatment in a peritoneal dialysis patient with secondary hyperparathyroidism and osteoporosis. A 58-year-old Caucasian female has been receiving chronic ambulatory peritoneal dialysis for four years secondary to polycystic kidney disease. Laboratory studies revealed: albumin-corrected calcium 9.0 mg/dL, phosphorus 5 mg/dL, alkaline phosphatase (ALP) 58 U/L [normal, 40-105], albumin 3.4 gm/dL [normal, 3.6-5.4] and intact parathyroid hormone (PTH) 315 pg/mL [normal, 40-72]. Marked osteoporosis was noted on the DXA scan, preventing her from renal transplantation considerations. She had failed conventional medical treatment, including per os calcium, monthly ergocalciferol (50,000 units/month), activated vitamin-D analog (doxercalciferol) and renal-failure adjusted alendronate (70 mg twice a month). She was started on subcutaneous denosumab 60 mg every 6 months. After her first dose, she developed a progressive drop of calcium, phosphorus, bicarbonate and magnesium, in spite of massive escalation of doxercalciferol and calcium supplementation. Hypocalcemia nadired at 6.3 mg/dL with symptomatic tetany, requiring a brief hospitalization approximately 7 weeks after denosumab treatment. Her elevated PTH rose further transiently (647 pg/mL), along with ALP (123 U/L). Bone-mineral parameters normalized approximately 3 months after denosumab administration. The observed phenomenon resembled the phenotype of “hungry bone syndrome” observed after surgical parathyroidectomy.
Conclusion: Treatment decisions based on bone densitometry results alone are not transposable between patients with or without end-stage renal disease. Denosumab may lead to critical hypocalcemia in dialysis patients and further aggravate existing secondary hyperparathyroidism.

 

Keywords :

Denosumab; end-stage renal disease; hungry bone syndrome; hypocalcemia; osteoporosis; RANK ligand inhibitor; tetany.

 

Review History    Comments


Search this site

Advanced Search

Announcement & News

ISI, Scopus, SJR, CAB, etc included PLANT CELL BIOTECHNOLOGY AND MOLECULAR BIOLOGY

ISI Thomson Reuters, Scopus, SCImago Journal & Country Rank (SJR), CAB, etc included PLANT CELL ...

SCIENCEDOMAIN international received 5844 submissions in 2013

SCIENCEDOMAIN international is pleased to announce that it has received 5844 submissions in 2013, ac...

ISI Thomson Reuters included Annual Research and Review in Biology

ISI Thomson Reuters included Annual Research and Review in Biology (http://science.thomsonreuters.co...

Science (IF: 31) report confirmed the high standard of SDI journal

As per a recent report (Link) of Science journal (present Impact factor 31), one of our journal (Bri...

Polish Ministry of Science and Higher Education included 18 SDI journals in its official report of 2013

SDI is pleased to announce that Polish Ministry of Science and Higher Education included 18 SDI jour...

SDI introduced Post-publication peer review by its comment section

SDI journals encourage Post-publication peer review by its comment section   Policy details a...

SDI promotes transparent Advanced OPEN peer review

We have migrated to transparent and toughest ‘Advanced OPEN peer review’ system (Detaile...

SCIENCEDOMAIN international received over 5000 submissions in 2013 (till 25th November, 2013)

SCIENCEDOMAIN international is pleased to announce that it has received over 5000 submissions in 201...



SCIENCEDOMAIN Awards

Browser Compatibility : Mozila firefox, Google Crome and IE 7 & above. Creative Commons License Terms & Condition  |  Privacy Policy  |  Join Us  |  Help  |  Contact Us
© Copyright 2010-2014, SCIENCEDOMAIN international. All rights reserved.